Brookline Capital Markets Estimates UNCY FY2030 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Equities researchers at Brookline Capital Markets lifted their FY2030 EPS estimates for Unicycive Therapeutics in a research note issued to investors on Tuesday, June 30th. Brookline Capital Markets analyst K. Raja now anticipates that the company will post earnings of $3.06 per share for the year, up from their prior forecast of $2.93. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.32) per share.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.08).

Several other research analysts have also issued reports on the stock. Wall Street Zen lowered shares of Unicycive Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 27th. Weiss Ratings raised Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 9th. HC Wainwright lowered their price objective on Unicycive Therapeutics from $22.00 to $15.00 and set a “buy” rating on the stock in a research note on Tuesday. B. Riley Financial reissued a “buy” rating and issued a $22.00 target price on shares of Unicycive Therapeutics in a report on Tuesday. Finally, Benchmark cut their target price on Unicycive Therapeutics from $18.00 to $13.00 and set a “speculative buy” rating for the company in a research report on Wednesday. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $27.40.

Unicycive Therapeutics Stock Performance

NASDAQ:UNCY opened at $5.28 on Thursday. The company has a 50-day moving average of $7.46 and a 200-day moving average of $6.82. Unicycive Therapeutics has a 52 week low of $3.71 and a 52 week high of $8.74. The company has a market capitalization of $144.62 million, a price-to-earnings ratio of -2.39 and a beta of 1.80.

Institutional Investors Weigh In On Unicycive Therapeutics

A number of large investors have recently bought and sold shares of UNCY. Lazard Asset Management LLC acquired a new stake in Unicycive Therapeutics during the 2nd quarter valued at $55,000. JPMorgan Chase & Co. grew its holdings in shares of Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after purchasing an additional 21,525 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Unicycive Therapeutics during the first quarter worth $161,000. Bank of America Corp DE increased its stake in shares of Unicycive Therapeutics by 19,327.6% in the first quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock valued at $194,000 after buying an additional 29,378 shares in the last quarter. Finally, Quadrature Capital Ltd acquired a new stake in shares of Unicycive Therapeutics in the fourth quarter valued at $226,000. 40.42% of the stock is currently owned by institutional investors.

Key Unicycive Therapeutics News

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: Noble Financial and Brookline Capital Markets reiterated a constructive long-term view, with Noble assigning an Outperform rating and $50 target while modeling strong 2027 earnings and Brookline raising its FY2030 EPS estimate. Analyst target update
• Positive Sentiment: Despite the FDA setback, the company said the agency did not raise concerns about OLC’s clinical efficacy or safety data and requested no additional clinical data, which leaves the door open for a future resubmission. FDA CRL summary
• Neutral Sentiment: Unicycive said it is in ongoing discussions with the FDA over labeling and packaging and remains optimistic about resolving the manufacturing issues, but there is still no clear timeline for approval. Investigation notice
• Negative Sentiment: Multiple law firms launched securities-fraud investigations into Unicycive after the FDA rejection, adding legal and reputational overhang for shareholders. Investor alert
• Negative Sentiment: Benchmark, Noble Financial, and HC Wainwright all lowered price targets, reflecting reduced near-term confidence after the regulatory setback. Price target cuts

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.